These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 26104439)

  • 21. Computational mapping tools for drug discovery.
    Ivanenkov YA; Savchuk NP; Ekins S; Balakin KV
    Drug Discov Today; 2009 Aug; 14(15-16):767-75. PubMed ID: 19520185
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Structure versus function-The impact of computational methods on the discovery of specific GPCR-ligands.
    Bermudez M; Wolber G
    Bioorg Med Chem; 2015 Jul; 23(14):3907-12. PubMed ID: 25828056
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Investigating drug-target association and dissociation mechanisms using metadynamics-based algorithms.
    Cavalli A; Spitaleri A; Saladino G; Gervasio FL
    Acc Chem Res; 2015 Feb; 48(2):277-85. PubMed ID: 25496113
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A new era of antibody discovery: an in-depth review of AI-driven approaches.
    Cheng J; Liang T; Xie XQ; Feng Z; Meng L
    Drug Discov Today; 2024 Jun; 29(6):103984. PubMed ID: 38642702
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A computational approach for studying antibody-antigen interactions without prior structural information: the anti-testosterone binding antibody as a case study.
    Koivuniemi A; Takkinen K; Nevanen T
    Proteins; 2017 Feb; 85(2):322-331. PubMed ID: 27936519
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High-Throughput Antibody Structure Modeling and Design Using ABodyBuilder.
    Leem J; Deane CM
    Methods Mol Biol; 2019; 1851():367-380. PubMed ID: 30298409
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tackling the conformational sampling of larger flexible compounds and macrocycles in pharmacology and drug discovery.
    Chen IJ; Foloppe N
    Bioorg Med Chem; 2013 Dec; 21(24):7898-920. PubMed ID: 24184215
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Computational Tools for Aiding Rational Antibody Design.
    Krawczyk K; Dunbar J; Deane CM
    Methods Mol Biol; 2017; 1529():399-416. PubMed ID: 27914064
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In Silico Methods in Antibody Design.
    Zhao J; Nussinov R; Wu WJ; Ma B
    Antibodies (Basel); 2018 Jun; 7(3):. PubMed ID: 31544874
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lessons learned from the design of chemical space networks and opportunities for new applications.
    Vogt M; Stumpfe D; Maggiora GM; Bajorath J
    J Comput Aided Mol Des; 2016 Mar; 30(3):191-208. PubMed ID: 26945865
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Beyond profiling: using ADMET models to guide decisions.
    Segall M; Champness E; Obrezanova O; Leeding C
    Chem Biodivers; 2009 Nov; 6(11):2144-51. PubMed ID: 19937845
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PDB-based protein loop prediction: parameters for selection and methods for optimization.
    van Vlijmen HW; Karplus M
    J Mol Biol; 1997 Apr; 267(4):975-1001. PubMed ID: 9135125
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Active-learning strategies in computer-assisted drug discovery.
    Reker D; Schneider G
    Drug Discov Today; 2015 Apr; 20(4):458-65. PubMed ID: 25499665
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fragment informatics and computational fragment-based drug design: an overview and update.
    Sheng C; Zhang W
    Med Res Rev; 2013 May; 33(3):554-98. PubMed ID: 22430881
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Navigating the Future of Cardiovascular Drug Development-Leveraging Novel Approaches to Drive Innovation and Drug Discovery: Summary of Findings from the Novel Cardiovascular Therapeutics Conference.
    Povsic TJ; Scott R; Mahaffey KW; Blaustein R; Edelberg JM; Lefkowitz MP; Solomon SD; Fox JC; Healy KE; Khakoo AY; Losordo DW; Malik FI; Monia BP; Montgomery RL; Riesmeyer J; Schwartz GG; Zelenkofske SL; Wu JC; Wasserman SM; Roe MT
    Cardiovasc Drugs Ther; 2017 Aug; 31(4):445-458. PubMed ID: 28735360
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Structure-Guided Design of Antibodies.
    Caravella JA; Wang D; Glaser SM; Lugovskoy A
    Curr Comput Aided Drug Des; 2010; 6(2):128-38. PubMed ID: 26845329
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Biophysical and computational fragment-based approaches to targeting protein-protein interactions: applications in structure-guided drug discovery.
    Winter A; Higueruelo AP; Marsh M; Sigurdardottir A; Pitt WR; Blundell TL
    Q Rev Biophys; 2012 Nov; 45(4):383-426. PubMed ID: 22971516
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Overview on the use of therapeutic antibodies in drug discovery.
    Roguska M; Kaymakcalan Z; Salfeld J
    Curr Protoc Pharmacol; 2005 Jan; Chapter 9():Unit 9.7. PubMed ID: 22294129
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Protein loop modeling using a new hybrid energy function and its application to modeling in inaccurate structural environments.
    Park H; Lee GR; Heo L; Seok C
    PLoS One; 2014; 9(11):e113811. PubMed ID: 25419655
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The interplay between molecular modeling and chemoinformatics to characterize protein-ligand and protein-protein interactions landscapes for drug discovery.
    Medina-Franco JL; Méndez-Lucio O; Martinez-Mayorga K
    Adv Protein Chem Struct Biol; 2014; 96():1-37. PubMed ID: 25443953
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.